Clinical Trials Directory

Trials / Sponsors / ProQR Therapeutics

ProQR Therapeutics

Industry · 7 registered clinical trials.

StatusTrialPhaseStarted
WithdrawnStudy With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium Molecular Biomarker(s) in Subjects W
Fuchs Endothelial Corneal Dystrophy, FECD3, Corneal Diseases
Phase 12021-08-10
UnknownAn Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerabil
Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis
Phase 2 / Phase 32021-03-23
Active Not RecruitingA Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigme
Autosomal Dominant Retinitis Pigmentosa, Eye Diseases, Eye Diseases, Hereditary
Phase 1 / Phase 22019-10-07
Active Not RecruitingA Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in
Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis
Phase 2 / Phase 32019-04-04
CompletedStudy to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the US
Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind
Phase 1 / Phase 22019-03-06
CompletedExploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR Mutation
Cystic Fibrosis
Phase 12015-09-01
CompletedDose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients
Cystic Fibrosis
Phase 1 / Phase 22015-06-01